Inflammatory bowel disease. Medical therapy of specific clinical presentations (Q34745614)

4 August 2017

1 reference

title

Inflammatory bowel disease. Medical therapy of specific clinical presentations (English)

1 reference

inflammatory bowel diseases

4 August 2017

main subject

0 references

inflammation

0 references

author name string

Subhas Banerjee

series ordinal

1

1 reference

4 August 2017

Mark A Peppercorn

series ordinal

2

1 reference

4 August 2017

publication date

1 March 2002

1 reference

Gastroenterology Clinics of North America

4 August 2017

published in

1 reference

4 August 2017

volume

31

1 reference

4 August 2017

issue

1

1 reference

4 August 2017

page(s)

185-202, x

1 reference

Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Sucralfate and hydrocortisone enemas in the treatment of active ulcerative proctitis--a randomized single-blind comparative study

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Topical treatment of ulcerative proctitis with lidocaine

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

The efficacy of tobramycin in the treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

A controlled double blind study of azathioprine in the management of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC)

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term responses

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Mesalamine and relapse prevention in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Smoking habits and recurrence in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Pharmacokinetics of budesonide enema in patients with distal ulcerative colitis or proctitis.

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571.

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Treatment of corticosteroid-resistant ulcerative colitis with heparin--a report of 16 cases.

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Clinical experience with infliximab therapy in 100 patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis. A comparison of the efficacy and practicality of two topical treatment regimens

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Low-Dose Cyclosporine for the Treatment of Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Methotrexate for the Treatment of Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Sequential treatment of anemia in ulcerative colitis with intravenous iron and erythropoietin

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Randomised controlled trial of azathioprine withdrawal in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal?

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Controlled trial comparing olsalazine and sulphasalazine for maintenance treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Azathioprine in ulcerative colitis: final report on controlled therapeutic trial.

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Endoscopic balloon dilatation of duodenal strictures in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Optimum duration of treatment with 6-mercaptopurine for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Controlled trial of azathioprine in chronic ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Methotrexate for the treatment of refractory Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Preliminary report: cyclosporin in treatment of severe active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

The role of azathioprine in the management of ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Budesonide versus prednisolone retention enemas in active distal ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Intravenous azathioprine in severe ulcerative colitis: a pilot study.

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Long-Term Outcome of Endoscopic Balloon Dilation in Obstructive Gastroduodenal Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine.

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Efficacy of cyclosporine in treatment of fistula of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Transdermal nicotine for active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

A comparison of budesonide with prednisolone for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Treatment of ulcerative colitis with fish oil n--3-omega-fatty acid: an open trial.

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Efficacy of intravenous cyclosporine for steroid refractory attacks of ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Second trial of mesalamine therapy in the treatment of active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

A preliminary study of growth hormone therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Tripotassium dicitrato bismuthate enemas in the treatment of ulcerative proctitis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Dietary Supplementation with Fish Oil in Ulcerative Colitis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Double blind, placebo controlled trial of metronidazole in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

5-Aminosalicylic acid enemas in treatment of distal ulcerative colitis and proctitis in Canada

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Effect of cigarette smoking on recurrence of Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Budesonide enema in distal ulcerative colitis. A randomized dose-response trial with prednisolone enema as positive control. The Danish Budesonide Study Group

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Transdermal nicotine as maintenance therapy for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

Thalidomide for the treatment of oral aphthous ulcers in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(01)50012-7

7 January 2021

10.1016/S0889-8553(01)00012-7

Identifiers

DOI

1 reference

4 August 2017

1 reference